- Home
- NBR vs MLTX Comparison
NBR vs MLTX Comparison
Compare NBR & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBR
- MLTX
- Stock Information
- Founded
- NBR 1952
- MLTX 2021
- Country
- NBR Bermuda
- MLTX Switzerland
- Employees
- NBR N/A
- MLTX N/A
- Industry
- NBR Oil & Gas Production
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- NBR Energy
- MLTX Health Care
- Exchange
- NBR Nasdaq
- MLTX Nasdaq
- Market Cap
- NBR 617.4M
- MLTX 595.6M
- IPO Year
- NBR N/A
- MLTX N/A
- Fundamental
- Price
- NBR $47.25
- MLTX $10.02
- Analyst Decision
- NBR Hold
- MLTX Buy
- Analyst Count
- NBR 8
- MLTX 9
- Target Price
- NBR $46.63
- MLTX $37.63
- AVG Volume (30 Days)
- NBR 336.2K
- MLTX 8.4M
- Earning Date
- NBR 10-28-2025
- MLTX 11-07-2025
- Dividend Yield
- NBR N/A
- MLTX N/A
- EPS Growth
- NBR N/A
- MLTX N/A
- EPS
- NBR N/A
- MLTX N/A
- Revenue
- NBR $3,030,598,000.00
- MLTX N/A
- Revenue This Year
- NBR $9.86
- MLTX N/A
- Revenue Next Year
- NBR $0.84
- MLTX N/A
- P/E Ratio
- NBR N/A
- MLTX N/A
- Revenue Growth
- NBR 3.49
- MLTX N/A
- 52 Week Low
- NBR $23.27
- MLTX $5.95
- 52 Week High
- NBR $86.10
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- NBR 67.11
- MLTX 28.03
- Support Level
- NBR $39.18
- MLTX $8.92
- Resistance Level
- NBR $41.40
- MLTX $10.08
- Average True Range (ATR)
- NBR 2.38
- MLTX 0.60
- MACD
- NBR 0.57
- MLTX 1.63
- Stochastic Oscillator
- NBR 89.14
- MLTX 52.56
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.